ClinVar Miner

Submissions for variant NM_000179.2(MSH6):c.3961A>G (p.Arg1321Gly) (rs41295278)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 13
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000115425 SCV000186831 uncertain significance Hereditary cancer-predisposing syndrome 2018-03-30 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence
CSER_CC_NCGL; University of Washington Medical Center RCV000148646 SCV000190361 uncertain significance Colorectal cancer, early onset 2014-06-01 no assertion criteria provided research
Clinical Genomics Lab,St. Jude Children's Research Hospital RCV000761131 SCV000891047 uncertain significance Myelodysplastic Syndrome with Single Lineage Dysplasia 2016-10-31 no assertion criteria provided clinical testing
Color RCV000115425 SCV000685469 uncertain significance Hereditary cancer-predisposing syndrome 2018-10-08 criteria provided, single submitter clinical testing
Counsyl RCV000410058 SCV000487938 uncertain significance Hereditary nonpolyposis colorectal cancer type 5 2015-12-06 criteria provided, single submitter clinical testing
GeneDx RCV000590664 SCV000149334 uncertain significance not provided 2018-06-22 criteria provided, single submitter clinical testing This variant is denoted MSH6 c.3961A>G at the cDNA level, p.Arg1321Gly (R1321G) at the protein level, and results in the change of an Arginine to a Glycine (AGA>GGA). This variant has been reported in individuals with early-onset colorectal cancer (CRC), pancreatic cancer, and in one individual with a personal history of Lynch syndrome-associated cancer and/or polyps (Pinto 2006, Barneston 2008, Yurgelun 2015, Jansen 2016, Shindo 2017). This variant was also reported to co-occur with an MSH2 pathogenic deletion in a patient with mismatch repair-deficient CRC (Le 2017). MSH6 Arg1321Gly was observed at an allele frequency of 0.03% (35/124,972) in individuals of European ancestry in large population cohorts (Lek 2016). MSH6 Arg1321Gly is located within an MSH2 binding site and the ATPase domain (Kariola 2002, Warren 2007, Kansikas 2011). In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether MSH6 Arg1321Gly is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Integrated Genetics/Laboratory Corporation of America RCV000202255 SCV000695903 likely benign not specified 2019-05-30 criteria provided, single submitter clinical testing MSH6 c.3961A>G (p.Arg1321Gly) results in a non-conservative amino acid change located in the DNA mismatch repair protein MutS, C-terminal (IPR000432) domain, comprised of the ATPase domain and the HTH (helix-turn-helix) domain, the latter being involved in dimer contacts (InterPro). Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00014 in 251114 control chromosomes (gnomAD and publication data). The variant was predominantly observed within the Non-Finnish European subpopulation at a frequency of 0.00028 in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 2 fold of the estimated maximal expected allele frequency for a pathogenic variant in MSH6 causing Lynch Syndrome phenotype (0.00014), suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. The c.3961A>G variant has been reported in the literature in individuals affected with Lynch Syndrome (Pinto 2006, Barneston 2008, Yurgelun 2015, Jansen 2016), Cowden/Cowden-like (CS/CS-like) or Bannayan-Riley-Ruvalcaba syndromes (Yehia 2018). These reports however do not provide unequivocal conclusions about association of the variant with Lynch Syndrome (i.e. lack of co-segregation data). UMD database reported the variant in 3 patients and one patient was indicated to carry another pathogenic MSH6 variant (c.3514dup (p.Arg1172LysfsX5)), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Nine other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and classified the variant as VUS (8x) or likely benign (1x). Based on the evidence outlined above, the variant was classified as likely benign.
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000074958 SCV000108173 uncertain significance Lynch syndrome 2013-09-05 reviewed by expert panel research Insufficient evidence
Invitae RCV000524199 SCV000283832 likely benign Hereditary nonpolyposis colon cancer 2018-01-05 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000202255 SCV000712603 uncertain significance not specified 2016-12-08 criteria provided, single submitter clinical testing The p.Arg1321Gly variant in MSH6 has been reported in at least 2 individuals wit h colorectal cancer (Pinto 2006, Barnetson 2008). It has also been found in one individual who had a second pathogenic variant in MSH6 (p.Arg1172fs, Universal M utation Database http://139.124.156.133/4D_molecules/UMD224708.html) and one ind ividual who carried two additional variants in MSH2 (p.Tyr165Asp and p.Asn596del , InSiGHT databse http://chromium.lovd.nl/LOVD2/colon_cancer/variants.php), alth ough no clinical information is available for these individuals. This variant ha s been identified in 19/65036 European chromosomes by the Exome Aggregation Cons ortium (ExAC, http://exac.broadinstitute.org; dbSNP rs41295278). Computational p rediction tools and conservation analysis do not provide strong support for or a gainst an impact to the protein. In summary, the clinical significance of the p. Arg1321Gly variant is uncertain.
Mayo Clinic Genetic Testing Laboratories,Mayo Clinic RCV000202255 SCV000257289 uncertain significance not specified no assertion criteria provided research
Mendelics RCV000074958 SCV000837926 uncertain significance Lynch syndrome 2018-07-02 criteria provided, single submitter clinical testing
PreventionGenetics RCV000590664 SCV000805900 uncertain significance not provided 2017-07-14 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.